Aligos Therapeutics (5WK0) Stock Price & Analysis
5WK0 Stock Chart & Stats
- Day’s Range
- EUR 4.24 - EUR 4.35
- 52-Week Range
- EUR 3.50 - EUR 11.10
- Previous Close
- EUR 4.30
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 26.80M
- Enterprise Value
- EUR 33.27M
- Total Cash (Recent Filing)
- EUR 30.38M
- Total Debt (Recent Filing)
- EUR 3.50M
- Price to Earnings (P/E)
- ―
- Beta
- 1.51
- Next Earnings
- Mar 11, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
High Gross Margin
The reported gross margin indicates that ALGS’s revenue carries strong economics before operating expenses. If the company can expand programs or commercialize candidates, this margin profile could provide meaningful operating leverage, although current revenue remains too small to cover its cost base.
Modest Leverage
Low debt relative to equity limits refinancing pressure and reduces fixed financial obligations compared with more heavily leveraged businesses. This gives ALGS greater flexibility to direct capital toward research and development, despite broader balance-sheet sensitivity from accumulated losses.
Lease Flexibility
The lease amendment offers a meaningful period of rent relief and includes defined termination flexibility, which can reduce facilities-related cash commitments over the medium term. These provisions may help management adjust its real-estate footprint as development needs and liquidity priorities evolve.
Bears Say
Persistent Unprofitability
Persistent operating and net losses show that ALGS’s current revenue base does not support its expense structure. Unless development activity produces substantially greater revenue or operating costs decline, ongoing deficits will continue to weaken retained capital and limit internally funded investment.
Structural Cash Burn
Materially negative operating and free cash flow indicate that the business is not self-funding and must continue relying on available liquidity or external capital. Sustained cash consumption can constrain research priorities and increase the likelihood of future financing or dilution.
Revenue Contraction And Balance-Sheet Fragility
Declining trailing revenue reduces the base available to absorb research and corporate expenses, while previously negative equity demonstrates sensitivity to accumulated losses. Together, these factors make financial recovery more dependent on successful development progress and improved operating performance.
Aligos Therapeutics News
Aligos Hepatitis B Trial Completion: What Phase 1 Liver Data Mean for ALGS Investors
Aligos Therapeutics, Inc. ($ALGS) announced an update on their ongoing clinical study. Aligos Hepatitis B Study Shows Progress in Liver-Impaired Patients. This Phase 1 study, titled “A Phase 1 Non-Randomized,
5WK0 FAQ
What was Aligos Therapeutics’s price range in the past 12 months?
What is Aligos Therapeutics’s market cap?
When is Aligos Therapeutics’s upcoming earnings report date?
How were Aligos Therapeutics’s earnings last quarter?
Is Aligos Therapeutics overvalued?
Does Aligos Therapeutics pay dividends?
What is Aligos Therapeutics’s EPS estimate?
How many shares outstanding does Aligos Therapeutics have?
What happened to Aligos Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Aligos Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Aligos Therapeutics
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials. Additionally, Aligos is advancing ALG-020572, an antisense oligonucleotide designed to stop HBsAg translation and secretion. Its portfolio also features siRNA drug candidates, including ALG-125755, ALG-125097, and ALG-125819, which have demonstrated potent capabilities in inhibiting HBsAg release from HBV-infected cells. For non-alcoholic steatohepatitis (NASH), the company is developing ALG-055009, a small molecule THR-ß agonist, now in Phase 1a/1b studies. Aligos has also forged several strategic alliances. These include licensing and collaboration with Luxna Biotech Co., Ltd. for HBV genome-targeting oligonucleotides, a partnership with Emory University for HBV capsid assembly modulator technology, an agreement with Katholieke Universiteit Leuven for the development of coronavirus protease inhibitors, and a deal with Merck to research and develop NASH-focused oligonucleotides. Established in 2018, Aligos Therapeutics is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Lawrence Blatt
- Employees
- 82
- Website
- www.aligos.com
- Address
- One Corporate Drive, South San Francisco, CA, 94080, US
Aligos Therapeutics (5WK0) Earnings & Revenues
5WK0 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 4 | 12 |
| Technical Analysis | 3 | 4 | 3 |
| Moving Averages | 3 | 0 | 9 |
